| Market Cap | 5.86M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.83M |
| Shares Out | n/a |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 251,500 |
| Average Volume | 1,619,773 |
| Open | 0.0232 |
| Previous Close | 0.0234 |
| Day's Range | 0.0210 - 0.0234 |
| 52-Week Range | 0.0160 - 0.0620 |
| Beta | -0.14 |
| RSI | 40.62 |
| Earnings Date | Jun 27, 2025 |
About BioVaxys Technology
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer... [Read more]
News
BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture
Submission Process Underway for Regulatory Approval of SpayVac in Feral Horses and Free-Ranging Deer Populations VANCOUVER, BC and MADISON, Wis. , April 22, 2025 /PRNewswire/ -- BioVaxys Technology Co...
BioVaxys Technology Corp. to Present at the Emerging Growth Conference on Thursday January 16, 2025
BioVaxys Technology Corp. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference. VANCOUVER...
BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up
VANCOUVER, BC , Dec. 17, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that in anticipation of restarting cl...
BIOVAXYS PARTNER SPAYVAC FOR WILDLIFE, INC., SCALES-UP VACCINE PRODUCTION CAPACITY
MADISON, Wis. , Nov. 20, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to jointly announce that SpayVac f...
BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium
VANCOUVER, BC , Nov. 5, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has been invited to and joined...
BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems
Study Results Position Company to Target Segments of $270B+ Multi-Billion Dollar Drug Delivery Systems Market 1 VANCOUVER, BC , Oct. 31, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA...
BioVaxys to Present at the Emerging Growth Conference on October 30th, 2024
BioVaxys invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation on the Emerging Growth Conference. VANCOUVER, BC , Oct. 28, 2...
BioVaxys Engages Dr. Rajkannan Rajagopalan as Vaccine Formulations Advisor
VANCOUVER, BC , Oct. 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Rajkannan Rajagopalan, PhD, as A...
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.com BioVaxys invites individual and institutional investor...
BioVaxys to Present at the Life Sciences Investor Forum on September 19th
BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.com VANCOUVER, BC , Sept. 12, 2024 /PRNewswire/ -- BioVaxy...
BioVaxys to Present New Data on its DPX Immune Educating Platform at Personalized Cancer Vaccine Summit
VANCOUVER, BC , Sept. 4, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") is pleased to announce that it has been invited to present "A...
BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases
VANCOUVER, BC , Aug. 22, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights the potential of its novel lipid-in-oil delivery ...
SPAYVAC FOR WILDLIFE, INC. ANNOUNCES COMPLETION OF SPAYVAC RESEARCH AND PRODUCTION FACILITY IN MADISON, WISCONSIN
MADISON, Wis. , Aug. 19, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. ("SpayVac") jointly announce that SpayVac® rec...
Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies
VANCOUVER, BC , July 29, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical-stage biopharmaceutical company developing a por...
BIOVAXYS ANNOUNCES ISSUANCE OF DPX RELATED PATENT FROM THE U.S. PATENT AND TRADEMARK OFFICE
VANCOUVER, BC , July 23, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that the United States Patent and Trademark Office ("U...
Brittany Davison, CPA, CA, Joins BioVaxys as Business Advisor
VANCOUVER, BC , July 18, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Brittany Davison, CPA, CA as Bu...
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF TRIAL TO TEST IMMUNOCONTRACEPTION IN ASIAN ELEPHANTS
VANCOUVER, BC and MADISON, Wis. , July 17, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac-for-Wildlife, Inc. ("SpayVac") jointly announce...
BioVaxys Technology Corp. Announces Revocation of Cease Trade Order
VANCOUVER, BC , July 12, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) (the "Company") is pleased to announce the revocation of the failure to file cease trade ord...
BioVaxys Technology Corp. Announces Failure to File Cease Trade Order
VANCOUVER, BC , May 16, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") announces that the Ontario Securities Commission (the "OSC") has issued a f...
CSE Bulletin: Suspension - BioVaxys Technology Corp. (BIOV)
Toronto, Ontario--(Newsfile Corp. - Le 16 mai/May 2024) - Effective immediately, BioVaxys Technology Corp. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defi...
BIOVAXYS APPOINTS CHRISTOPHER CHERRY AS CHIEF FINANCIAL OFFICER
VANCOUVER, BC , April 30, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has appointed Christopher Cherry as Chief ...
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
VANCOUVER, BC , April 18, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is providing this bi-weekly update on the status of the management cease ...
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
VANCOUVER, BC, and MADISON, Wis. , April 10, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac-for-Wildlife, Inc. ("SpayVac") jointly announ...
BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE
VANCOUVER, B.C. , April 3, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has received a Notice of Allowance from the ...
BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order
VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the ...